These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25081631)

  • 1. A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck.
    Adkins D; Ley J; Dehdashti F; Siegel MJ; Wildes TM; Michel L; Trinkaus K; Siegel BA
    Cancer Med; 2014 Dec; 3(6):1493-501. PubMed ID: 25081631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.
    Schmitz S; Hamoir M; Reychler H; Magremanne M; Weynand B; Lhommel R; Hanin FX; Duprez T; Michoux N; Rommel D; Lonneux M; Cappoen N; Gillain A; Machiels JP
    Ann Oncol; 2013 Sep; 24(9):2261-6. PubMed ID: 23704200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
    J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early evaluation of neoadjuvant chemotherapy response using FDG-PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma.
    Kikuchi M; Nakamoto Y; Shinohara S; Fujiwara K; Yamazaki H; Kanazawa Y; Kurihara R; Kishimoto I; Harada H; Naito Y
    Int J Clin Oncol; 2013 Jun; 18(3):402-10. PubMed ID: 22402886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative Contrast-Enhanced CT Versus ¹⁸F-FDG PET/CT Evaluation and the Prognostic Value of Extranodal Extension for Surgical Patients with Head and Neck Squamous Cell Carcinoma.
    Lee JR; Choi YJ; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1020-7. PubMed ID: 26122372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma.
    Slevin F; Subesinghe M; Ramasamy S; Sen M; Scarsbrook AF; Prestwich RJ
    Br J Radiol; 2015 Aug; 88(1052):20140592. PubMed ID: 26081447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?
    Castaldi P; Rufini V; Bussu F; Miccichè F; Dinapoli N; Autorino R; Lago M; De Corso E; Almadori G; Galli J; Paludetti G; Giordano A; Valentini V
    Radiother Oncol; 2012 Apr; 103(1):63-8. PubMed ID: 22459579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic performance of
    Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
    Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Verhoeff SR; van de Donk PP; Aarntzen EHJG; Oosting SF; Brouwers AH; Miedema IHC; Voortman J; Menke-van der Houven van Oordt WC; Boellaard R; Vriens D; Slingerland M; Hermsen R; Grunsven IVE; Heskamp S; van Herpen CML
    J Nucl Med; 2022 Oct; 63(10):1523-1530. PubMed ID: 35512998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.
    Roh JL; Park JP; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Radiology; 2014 Apr; 271(1):153-61. PubMed ID: 24475791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG PET/CT and diffusion-weighted imaging of head and neck squamous cell carcinoma: comparison of prognostic significance between primary tumor standardized uptake value and apparent diffusion coefficient.
    Nakajo M; Nakajo M; Kajiya Y; Tani A; Kamiyama T; Yonekura R; Fukukura Y; Matsuzaki T; Nishimoto K; Nomoto M; Koriyama C
    Clin Nucl Med; 2012 May; 37(5):475-80. PubMed ID: 22475897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.
    Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N
    Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ¹⁸F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer.
    Delouya G; Igidbashian L; Houle A; Bélair M; Boucher L; Cohade C; Beaulieu S; Filion EJ; Coulombe G; Hinse M; Martel C; Després P; Nguyen-Tan PF
    Radiother Oncol; 2011 Dec; 101(3):362-8. PubMed ID: 21885143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT for detecting distant metastases in patients with recurrent head and neck squamous cell carcinoma.
    Yi JS; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY; Roh JL
    J Surg Oncol; 2012 Nov; 106(6):708-12. PubMed ID: 22674652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of
    Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
    Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma.
    Abgral R; Le Roux PY; Rousset J; Querellou S; Valette G; Nowak E; Turzo A; Tissot V; Marianowski R; Salaün PY
    Nucl Med Commun; 2013 Jun; 34(6):551-6. PubMed ID: 23587836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
    Lalami Y; Garcia C; Flamen P; Ameye L; Paesmans M; Awada A
    Head Neck; 2016 Mar; 38(3):347-54. PubMed ID: 25332069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer.
    Moeller BJ; Rana V; Cannon BA; Williams MD; Sturgis EM; Ginsberg LE; Macapinlac HA; Lee JJ; Ang KK; Chao KS; Chronowski GM; Frank SJ; Morrison WH; Rosenthal DI; Weber RS; Garden AS; Lippman SM; Schwartz DL
    J Clin Oncol; 2009 May; 27(15):2509-15. PubMed ID: 19332725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.